| 摘要 |
PROBLEM TO BE SOLVED: To provide an injectable depot formulation containing crystals of iloperidone or its metabolite, wherein release and absorption of its crystalline component in plasma can be correlated with a size of the crystals.SOLUTION: The present invention provides the injectable depot formulation which comprises iloperidone or its metabolite or its pharmaceutically acceptable salt, a hydrate, a solvate, a polymorphic or stereoisomeric crystal, wherein an Xvalue of the crystal ranges 1-200 μ. |
